Our study shows that the ovarian cancer microenvironment can regulate the metabolism and function of immunosuppressive CD11b ⁺ Gr1⁺ myeloid cells and modulate its immune microenvironment. Targeting glutamine metabolism via DLST in immunosuppressive myeloid cells decreased their activity, leading to a reduction in the immunosuppressive tumor microenvironment. Thus, targeting glutamine metabolism has the potential to enhance the success of immunotherapy in ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Udumula et al. (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: